Skip to main content

Table 2 Primary outcome

From: Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis

 

ARNI

(N = 87)

Standard treatment

(N = 100)

Crude HR

(95% CI),

p-value

Adjusted HR* (95% CI),

p-value

Primary composite outcome

 Mortality or hospitalization for heart failure

10 (11.5%)

28 (28.0%)

0.34 (0.15–0.80),

p = 0.013

0.32 (0.13–0.82),

p = 0.017

Component of composite outcome

 Mortality**

0 (0%)

4 (4.0%)

p = 0.125

 Hospitalization for heart failure

10 (11.5%)

26 (26.0%)

0.31 (0.13–0.73),

p = 0.007

  1. ARNI = angiotensin receptor/ neprilysin inhibitor, HR = hazard ratio
  2. *Cox-regression analysis adjusted by age, BMI, dilated cardiomyopathy, chronic kidney disease, use of cardiac resynchronization therapy, use of ivabradine
  3. **Fisher Exact test